POSTTitle: COVID-19_vaccine
ID: 982231713
In June, the [[Serum Institute of India]] (SII) – a major manufacturer of global vaccines – reached a licensing agreement with AstraZeneca to make {{nowrap |1 billion doses}} of vaccine for low-and-middle income countries; The Chinese government pledged in May that a successful Chinese vaccine would become a "global, public good," implying enough doses would be manufactured for both national and global distribution.
<td class="diff-addedline"><div>In June, the [[Serum Institute of India]] (SII) – a major manufacturer of global vaccines – reached a licensing agreement with AstraZeneca to make {{nowrap |1 billion doses}} of vaccine for low-and-middle income countries;&lt;ref name="kyle" /&gt; <ins class="diffchange diffchange-inline">of</ins> <ins class="diffchange diffchange-inline">which</ins> <ins class="diffchange diffchange-inline">half</ins> <ins class="diffchange diffchange-inline">of</ins> the doses <ins class="diffchange diffchange-inline">would</ins> <ins class="diffchange diffchange-inline">go</ins> <ins class="diffchange diffchange-inline">to</ins> <ins class="diffchange diffchange-inline">India</ins>.&lt;ref <ins class="diffchange diffchange-inline">name</ins>=<ins class="diffchange diffchange-inline">unequal</ins>/&gt; Similar preferential homeland distribution may exist if a vaccine is manufactured in Australia.&lt;ref name="khamsi"&gt;{{Cite journal|last=Khamsi|first=Roxanne|date=2020-04-09|title=If a coronavirus vaccine arrives, can the world make enough?|url=https://www.nature.com/articles/d41586-020-01063-8|journal=Nature|volume=580|issue=7805|pages=578–80|doi=10.1038/d41586-020-01063-8|pmid=32273621|bibcode=2020Natur.580..578K|doi-access=free|access-date=10 June 2020|archive-url=https://web.archive.org/web/20200513023042/https://www.nature.com/articles/d41586-020-01063-8|archive-date=13 May 2020|url-status=live | name-list-format = vanc }}&lt;/ref&gt; <ins class="diffchange diffchange-inline">The</ins> Chinese government pledged in May that a successful Chinese vaccine would become a "global, public good," implying enough doses would be manufactured for both national and global distribution.&lt;ref&gt;{{Cite news|last=Gretler|first=Corinne|title=China pledges to make its coronavirus vaccine a 'public good'|work=The National Post|publisher=Bloomberg|url=https://nationalpost.com/news/world/china-pledges-to-make-its-coronavirus-vaccine-a-public-good|access-date=2020-06-09|date=2020-05-18 | name-list-format = vanc }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985444369&oldid=982231713
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=982231713&oldid=982186183
Fuzzy: In June, the Serum Institute of India (SII) – a major manufacturer of global vaccines – reached a licensing agreement with AstraZeneca to make 1 billion doses of vaccine for low-and-middle income countries;[204] of which half of the doses would go to India.[209] Similar preferential homeland distribution may exist if a vaccine is manufactured in Australia.[210] The Chinese government pledged in May that a successful Chinese vaccine would become a "global, public good," implying enough doses would be manufactured for both national and global distribution.[211]



POSTTitle: COVID-19_vaccine
ID: 983355029
Temporarily paused on October 13 2020 due to an unexplained illness in a participant.
<td class="diff-addedline"><div>Temporarily paused on October 13 2020 due to an unexplained illness in a participant.&lt;ref&gt;{{Cite we|title=Johnson &amp; Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials|url=https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985444369&oldid=983355029
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=983355029&oldid=983352748
Fuzzy: Temporarily paused on October 13 2020 due to an unexplained illness in a participant.[114]



